What do systematic reviews say?

Dornase alfa vs dornase alfa and mannitol

Dornase alfa showed no clear difference in mean absolute change in FEV1 (L) at 3 months compared with dornase alfa and mannitol (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 0.1
  231 participants
  Low

Dornase alfa vs placebo or no dornase alfa treatment

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 320 participants
  Moderate
• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 647 participants
  High

Dornase alfa vs mannitol

Dornase alfa showed no clear difference in mean absolute change in FEV1 (L) at 3 months compared with mannitol (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 0.02
  231 participants
  Low

Dornase alfa vs hypertonic saline

Dornase alfa may leads to higher mean relative percentage in FEV1 (L) at 3 months compared with hypertonic saline (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 8 [2, 14]
  431 participants
  Low

Dornase alfa vs alternate days

Dornase alfa daily showed no clear difference in mean relative percentage change in FEV1 (L) at 3 months compared with alternate days (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 2
  43 participants
  Low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

The review found no eligible studies for this question.

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEV1mL (percentage change from baseline) compared with dornase alfa (very low certainty).

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low

Dornase alfa vs after airway clearance techniques

It is very uncertain whether inhalation of dornase alfa before changes FEV1 (% predicted) change from baseline compared with after airway clearance techniques (very low certainty).

• Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 0.83
  102 participants
  Very low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 85 participants
  Low